国际动态存档 （2015年8月1期）
- Drugs that turn cancer into a chronic disease need new marketing strategies: report
- Pfizer, Bristol revive cancer drugs that rev up immune system
- The alluring idea that we can cure cancer has become a trap
- Managing Platinum-Resistant Ovarian Cance
- Topical Gel Proves Safe, Effective Treatment for Patients with Skin T Cell Lymphoma, Penn Study Finds
- Big Pharma feels the pain in China, with AZ delivering the only 10%-plus sales hike
- Allergan's brands deliver sales beat in a good sign for generics-free future
- Precision medicine may leave public health efforts in the dust
- New Cancer Cocktails Expected to Test Price Ceilings, Immunotherapies are costly but offer long-lasting responses
- FDA launches open-source platform for precision medicine
- Generics Makers Will Continue to Consolidate; Prices Will Rise
- Combo Treatment May Boost Survival With Advanced Prostate Cancer
- Contraceptives May Lower Endometrial Cancer Risk Long-Term
- Dr Reddy’s to market Amgen’s three drugs in Indian market
- AstraZeneca widens cancer push with up to $500 mln Heptares deal
- The Dawn of the Age of Value Pricing in Cancer? Six implications of the proposed ASCO Value Framework in Cancer for U.S. Pharma and Biotech
- With $300M spent on potential split, Pfizer CEO now 'biased' toward branded M&A
- GSK rehires whistleblower linked to China bribery scandal
- With more consolidation on tap in generics, who's next to buy and be bought?
- Scripps team finds a drug that fights addiction by eliminating memories
- Surrogate endpoints may not predict OS in oncology clinical trials
- Pharma sales predicted to top $1.3 trillion by 2018
- Molecular tinkering doubles cancer drug's efficacy
- FDA acts to stop Sacramento tofu and sprout manufacturer from selling adulterated food
- Shire's $30 Billion Baxalta Bid Faces Big Hurdles
- Regeneron ups its research budget by 32% with eyes on new blockbusters
- BioMarin outlines its R&D game plan as Duchenne MD decision nears
- AstraZeneca deepens its Isis ties with a $65M R&D pact
- Can a dwindling rep tally keep Vivus' obesity med in the game?
- Lexicon Surges on Anti-Diarrhea Drug Success in Cancer Patients
- The 3 deadliest drugs in America are all totally legal
- Pharmaceutical Companies Race to Build CAR T-Cell Manufacturing Processes
- In Cancer Cost Debate, It's Oncologist vs. Oncologist
- Shire Offers to Buy Drug Maker Baxalta for $30 Billion
- FDA Approves The First 3D Printed Drug Product
- House moves to protect VA whistleblowers; Obama promises veto
- BeiGene Receives Approval to Initiate Clinical Trials in China With BGB-283 for Solid Tumor Cancers
- Immune Checkpoint Combination Strategies Evolving in NSCLC
- Clovis Oncology Completes U.S. and E.U. Regulatory Submissions for Rociletinib for the Treatment of Advanced EGFR-Mutant T790M+ Non-small Cell Lung Cancer
- Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies
- 路人丙: 新药发现的低悬果实
- Pipi_WHU: 新药发现的低悬果实
- 路人丙: Galapagos放弃IPF资产、吉利德空手而归
- Tan, Chengfang: Galapagos放弃IPF资产、吉利德空手而归
- 配体效率遭到质疑 | 美中药源: 你笑我无知类药性本不存在？
- Songdanqing: 你笑我无知类药性本不存在？
- 路人丙: 中国新药的新时代
- 康, 荣明: 中国新药的新时代
合作伙伴
微信号：美中药源